NCT06758544

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Guangdong Provincial People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.

Detailed description

This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer. The study is planned to enroll 18 subjects. The entire study consists of a screening period of up to 28 days, treatment period, and a follow-up period (safety follow-up 28 days after the final study dose and survival follow-up once every 3 months).

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Oncolytic virus VRT106	VRT106, IV
DRUG	Chemotherapy	21 days/cycle, administered up to 6 cycles

Timeline

• Start date: 2025-03-17
• Primary completion: 2026-09-30
• Completion: 2026-11-30
• First posted: 2025-01-03
• Last updated: 2025-08-17

Locations

1 site across 1 country: China